USFDA completes inspection at Aurobindo Pharma’s arm's Formulation facility in Telangana

27 Feb 2026 Evaluate

The United States Food and Drug Administration (USFDA) has inspected Unit-I, a Formulation manufacturing facility of Eugia Pharma Specialities, a wholly owned subsidiary of Aurobindo Pharma, situated at Kolthur Village, Shameerpet Mandal, Ranga Reddy, Telangana, from February 16, 2026 to February 27, 2026.

The inspection concluded with 4 observations. The company will respond to the US FDA within the stipulated timelines. The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1291.40 43.45 (3.48%)
20-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.45
Dr. Reddys Lab 1298.95
Cipla 1255.85
Zydus Lifesciences 890.60
Lupin 2322.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×